MQS Management LLC Purchases Shares of 17,468 Cellebrite DI Ltd. (NASDAQ:CLBT)

MQS Management LLC purchased a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 17,468 shares of the company’s stock, valued at approximately $294,000.

Other institutional investors also recently bought and sold shares of the company. Janney Montgomery Scott LLC increased its stake in shares of Cellebrite DI by 240.1% in the first quarter. Janney Montgomery Scott LLC now owns 45,300 shares of the company’s stock worth $502,000 after acquiring an additional 31,981 shares during the period. SG Americas Securities LLC grew its position in Cellebrite DI by 34.8% during the 1st quarter. SG Americas Securities LLC now owns 51,881 shares of the company’s stock worth $575,000 after purchasing an additional 13,392 shares during the period. Sei Investments Co. raised its stake in shares of Cellebrite DI by 44.7% during the 1st quarter. Sei Investments Co. now owns 121,166 shares of the company’s stock valued at $1,343,000 after buying an additional 37,408 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Cellebrite DI by 92.5% in the 1st quarter. Russell Investments Group Ltd. now owns 16,649 shares of the company’s stock valued at $188,000 after buying an additional 8,001 shares during the period. Finally, Acadian Asset Management LLC boosted its stake in shares of Cellebrite DI by 26.8% in the first quarter. Acadian Asset Management LLC now owns 2,896,497 shares of the company’s stock worth $32,062,000 after buying an additional 612,787 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Price Performance

CLBT stock opened at $17.96 on Friday. Cellebrite DI Ltd. has a 52 week low of $7.64 and a 52 week high of $21.00. The firm has a 50-day simple moving average of $17.70 and a 200-day simple moving average of $14.47.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05. The company had revenue of $106.90 million during the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. Cellebrite DI’s quarterly revenue was up 27.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.09 EPS. On average, analysts predict that Cellebrite DI Ltd. will post 0.31 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on CLBT shares. Lake Street Capital lifted their price target on Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Needham & Company LLC lifted their target price on shares of Cellebrite DI from $17.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Cellebrite DI from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, Bank of America upped their price objective on shares of Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $20.29.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.